A Study of MRG002 in the Treatment of HER2-positive/HER2-low Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer.
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Aiping Zhou, MD
Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College
Principal Investigator - Jin Li, MD
Shanghai Oriental Hospital
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, Beijing Municipality, China
Not, yet, recruiting - Hunan Cancer Hospital
Changsha, Hunan, China
Recruiting - Shanghai Oriental Hospital
Shanghai, Shanghai Municipality, China
Not, yet, recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 19 Jan 2022
- Primary completion
- 31 Dec 2023
- Completion
- 31 Dec 2023
- Last update posted
- 23 Feb 2022
- Registered enrollment
- 60
- Registry id
- NCT05141747
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.